Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity

Alcohol Use Disorder (AUD) contributes significantly to global mortality. GLP-1 (Glucagon-like peptide-1) and GLP-1/GIP (Glucose-dependent Insulinotropic Polypeptide) agonists, FDA-approved for managing type 2 diabetes and obesity, where the former has shown to effectively reduce the consumption of...

Descripción completa

Detalles Bibliográficos
Autores principales: Quddos, Fatima, Hubshman, Zachary, Tegge, Allison, Sane, Daniel, Marti, Erin, Kablinger, Anita S., Gatchalian, Kirstin M., Kelly, Amber L., DiFeliceantonio, Alexandra G., Bickel, Warren K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10684505/
https://www.ncbi.nlm.nih.gov/pubmed/38017205
http://dx.doi.org/10.1038/s41598-023-48267-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10684505/
https://www.ncbi.nlm.nih.gov/pubmed/38017205
http://dx.doi.org/10.1038/s41598-023-48267-2

Ejemplares similares